Organisation: Forest Laboratories

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

business

Forest Laboratories’ Irish subsidiary records loss

The main Irish subsidiary of pharmaceutical firm, Forest Laboratories, plunged into the red last year to record pre-tax losses of $138.42m (€126.29m).

business

Actavis to use Allergan name after $66bn takeover

business

Pharma firm’s profits quadruple to €341m

business

Flurry of Irish-linked merger deals

business

Actavis to buy Forest Labs for $25bn

business

Saga ends as Perrigo to buy Elan for $8.6bn

Elan offers no hints over timing of sale

Elan has said it is focused squarely on exploring a sale of the company, but has offered no potential transaction timeframe, nor hinted at any bid deadlines.

Thu, 25 Jul, 2013

Elan bids not expected until after results

First round takeover bids for Irish bio-tech firm Elan are not likely to be formally tabled until after the company publishes its half-year results later this month.

Tue, 16 Jul, 2013

Claim Forest mulling Elan bid

Forest Laboratories, the speciality drugmaker that counts investor Carl Icahn as a major shareholder, is among a handful of companies interested in bidding for Irish biotech firm Elan, sources claim.

Fri, 21 Jun, 2013

Forest Laboratories pre-tax profits tumble 47.5%

Pre-tax profits at the main Irish subsidiary of US- owned pharmaceutical firm, Forest Laboratories last year decreased by 47.5% to $626.5m (€489.6m).

Fri, 16 Nov, 2012

Firm pays €2.15bn dividend to US parent

THE main Irish subsidiary of US pharmaceutical firm, Forest Laboratories this year paid a dividend of $3 billion (€2.15bn) to its US parent, new figures show.

Fri, 29 Oct, 2010